Wells Fargo & Company Forecasts Strong Price Appreciation for AxoGen (NASDAQ:AXGN) Stock

AxoGen (NASDAQ:AXGN) had its target price hoisted by research analysts at Wells Fargo & Company from $48.00 to $56.00 in a report released on Thursday, Benzinga reports. The brokerage presently has an “overweight” rating on the medical equipment provider’s stock. Wells Fargo & Company‘s price target points to a potential upside of 14.40% from the company’s previous close.

A number of other research firms have also recently weighed in on AXGN. Wall Street Zen cut shares of AxoGen from a “buy” rating to a “hold” rating in a research note on Saturday, September 26th. Weiss Ratings reissued a “sell (d-)” rating on shares of AxoGen in a research report on Wednesday, August 26th. Morgan Stanley lowered shares of AxoGen to a “hold” rating in a research note on Tuesday, September 29th. Citizens Jmp lifted their price target on shares of AxoGen from $50.00 to $55.00 and gave the stock a “market outperform” rating in a report on Thursday, July 30th. Finally, Citigroup reiterated a “market outperform” rating on shares of AxoGen in a research note on Thursday, July 30th. Twelve equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $56.27.

AxoGen Stock Performance

Shares of NASDAQ AXGN traded down $0.30 during mid-day trading on Thursday, reaching $48.95. 131,550 shares of the company’s stock were exchanged, compared to its average volume of 1,191,204. The firm has a 50-day moving average price of $42.78 and a two-hundred day moving average price of $39.28. The company has a debt-to-equity ratio of 0.07, a current ratio of 6.60 and a quick ratio of 5.04. The firm has a market capitalization of $2.63 billion, a price-to-earnings ratio of -71.68 and a beta of 1.17. AxoGen has a 52 week low of $21.68 and a 52 week high of $52.91.

AxoGen (NASDAQ:AXGN) last posted its quarterly earnings results on Wednesday, October 28th. The medical equipment provider reported $0.21 earnings per share for the quarter, beating the consensus estimate of $0.13 by $0.08. The company had revenue of $75.83 million during the quarter, compared to analyst estimates of $73.18 million. AxoGen had a negative net margin of 13.36% and a negative return on equity of 8.90%. Analysts predict that AxoGen will post -0.44 EPS for the current year.

Insider Buying and Selling

In other AxoGen news, Director Joseph Tyndall sold 3,500 shares of the firm’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $49.70, for a total value of $173,950.00. Following the completion of the transaction, the director owned 10,650 shares in the company, valued at $529,305. This trade represents a 24.73% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marc Began sold 67,500 shares of AxoGen stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $47.34, for a total value of $3,195,450.00. Following the transaction, the executive vice president directly owned 50,135 shares of the company’s stock, valued at $2,373,390.90. The trade was a 57.38% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 98,503 shares of company stock worth $4,656,947 in the last 90 days. 2.44% of the stock is owned by company insiders.

Hedge Funds Weigh In On AxoGen

A number of large investors have recently modified their holdings of AXGN. State of Alaska Department of Revenue boosted its stake in AxoGen by 16.9% during the third quarter. State of Alaska Department of Revenue now owns 2,833 shares of the medical equipment provider’s stock valued at $118,000 after buying an additional 409 shares during the period. PNC Financial Services Group Inc. increased its stake in AxoGen by 6.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 8,943 shares of the medical equipment provider’s stock worth $296,000 after acquiring an additional 525 shares during the last quarter. Nykredit A S bought a new position in AxoGen in the 2nd quarter worth about $30,000. Arizona State Retirement System increased its stake in AxoGen by 7.6% in the 2nd quarter. Arizona State Retirement System now owns 13,604 shares of the medical equipment provider’s stock worth $628,000 after acquiring an additional 966 shares during the last quarter. Finally, Principal Financial Group Inc. raised its holdings in shares of AxoGen by 1.4% in the 1st quarter. Principal Financial Group Inc. now owns 89,745 shares of the medical equipment provider’s stock valued at $2,973,000 after acquiring an additional 1,210 shares in the last quarter. 80.29% of the stock is currently owned by institutional investors.

Key AxoGen News

Here are the key news stories impacting AxoGen this week:

• Positive Sentiment: Q3 earnings and revenue exceeded expectations. AxoGen reported adjusted earnings of $0.21 per share, versus the $0.13–$0.14 consensus range, while revenue increased to $75.83 million from an expected $73.18 million. Earnings also improved from $0.12 per share a year earlier. AxoGen Beats Q3 Earnings and Revenue Estimates
• Positive Sentiment: Management raised 2026 revenue guidance. AxoGen now expects full-year revenue of at least $290 million, representing minimum growth of 29%. The higher outlook signals continued demand for its peripheral nerve repair products and was a key catalyst for investor enthusiasm. AxoGen Reports Third Quarter 2026 Financial Results
• Positive Sentiment: HC Wainwright raised its price target to $56 from $53 and maintained a Buy rating. The revised target implies additional upside from the reported $49.25 reference price and reinforces the improving analyst view of AXGN’s growth prospects. HC Wainwright stock recommendations
• Positive Sentiment: Options activity reflected strong speculative interest. Investors purchased 9,886 call options, compared with average daily call volume of about 900, suggesting increased bullish positioning after the earnings release.
• Neutral Sentiment: Despite the earnings beat, AxoGen continues to report a negative net margin and negative return on equity. Its elevated valuation following the rally could also limit further gains unless revenue growth and profitability continue to improve. Does AxoGen Have More Upside?

About AxoGen

AxoGen, Inc (NASDAQ: AXGN) is a medical technology company focused on developing and commercializing products for the repair and regeneration of peripheral nerves. Its technologies are designed to help restore sensory and motor function following traumatic injuries, surgical procedures, and other conditions affecting peripheral nerves.

The company’s product portfolio includes Avance Nerve Graft, a processed human nerve allograft used to bridge gaps in damaged nerves without requiring tissue to be taken from another part of the patient’s body.